“阴伟达”？长春高新又有神药了？2万手封死涨停…

Core Viewpoint - The recent approval of GenSci141 ointment for clinical trials by Changchun High-tech has caused a significant surge in its stock price, with a funding lock-up of 200 million yuan, indicating strong market interest in the potential of this new drug [1][10]. Group 1: Product Approval and Market Potential - The GenSci141 ointment, a dihydrotestosterone formulation, is aimed at treating conditions like hypogonadism and 5α-reductase type 2 deficiency in children, addressing a previously unmet medical need as no specific drug has been approved globally for this purpose [2][11]. - There are over 500,000 existing patients with small penis syndrome in China, with an annual increase of 50,000 to 100,000 new cases. The peak sales forecast for the Chinese market is estimated between 1.5 billion to 2.5 billion yuan, with potential revenue of 2 billion yuan by 2030, contributing 800 million to 1 billion yuan in net profit, which would account for over 70% of Changchun High-tech's current net profit [2][11]. Group 2: Financial Performance and Forecast - Recently, the company issued a profit warning for 2025, projecting a net profit of only 150 million to 220 million yuan, a drastic decline of 91.48% to 94.19% compared to the 2.583 billion yuan net profit in 2024 [2][11]. - This significant drop in expected profits raises concerns about the company's financial health and the sustainability of its growth trajectory despite the promising outlook for the new drug [2][11].